Article

apnews.com on 2022-01-12 15:37

Biogen tumbles after Medicare lays out Aduhelm coverage plan - Wed, 12 Jan 2022 PST

Shares of Biogen slid Wednesday, a day after federal regulators slapped coverage limitations on the drugmaker’s new Alzheimer’s disease treatment.

Cambridge

Related news

HBiogen Tumbles After Medicare Lays Out Aduhelm Coverage Plan hamodia.com
Cambridge , Lays-sur-le-Doubs
Biogen tumbles after Medicare lays out Aduhelm coverage plan Seattle Times
Cambridge
Biogen seeks new chief, cuts Aduhelm spending Arkansas Online
Europe , Wall Street , Cambridge
Medicare Seeks To Limit Coverage For Controversial Alzheimer’s Drug Aduhelm Forbes
Massachusetts , Cambridge
Biogen CEO Stepping Down After Struggles With Alzheimer’s Drug Aduhelm Forbes
Cambridge
CMS “Splits the Baby” on Aduhelm—Medicare Coverage But Only with Evidence Development for Now jdsupra.com
United States
Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm WRAL
United States , Switzerland
Medicare Won’t Pay For Controversial Alzheimer’s Drug Aduhelm Without A New Trial Forbes
Cambridge
Change at the top at Biogen after struggles with Aduhelm Seattle Times
Massachusetts
Biogen plans to shut down its controversial Alzheimer’s drug Aduhelm Seattle Times
Japan
Medicare limits coverage of $28,000-a-year Alzheimer’s drug bangordailynews.com
Washington , Indianapolis , Cambridge
BBiogen Sold $1.6M of Aduhelm in Weeks After Approval. Earnings Were Strong.2 min read barrons.com
Medicare will limit coverage of pricey Alzheimer’s drug San Jose Mercury News
Medicare Officially Limits Coverage of Aduhelm in Clinical Trials The New York Times
Medicare will cover Aduhelm only for those enrolled in clinical trials POLITICO
Aduhelm, priced at $56,000 a year, is a key factor driving a up Medicare premiums CNN